BPMC - Blueprint Medicines Corporation
52.26 0.00 (0.00%)
After hours: 4:42PM EST
| Previous Close | 56.18 |
| Open | 55.96 |
| Bid | 51.63 x 1300 |
| Ask | 75.00 x 800 |
| Day's Range | 51.80 - 56.45 |
| 52 Week Range | 51.80 - 109.00 |
| Volume | 1,332,377 |
| Avg. Volume | 338,726 |
| Market Cap | 2.297B |
| Beta (3Y Monthly) | 1.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.09 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 100.50 |
- PR Newswire•11 hours ago
Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy
- 84% ORR in PDGFRα D842V GIST and 20% ORR in fourth-line or later GIST support plans to submit New Drug Application to FDA in the first half of 2019 - - 26% ORR in regorafenib-naïve third- and fourth-line ...
Markit•6 days agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- Thomson Reuters StreetEvents•9 days ago
Edited Transcript of BPMC earnings conference call or presentation 30-Oct-18 12:30pm GMT
Q3 2018 Blueprint Medicines Corp Earnings Call
- GlobeNewswire•10 days ago
Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•16 days ago
Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.73% and -45.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•16 days ago
Blueprint Medicines: 3Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of $1.66 per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- PR Newswire•16 days ago
Blueprint Medicines Reports Third Quarter 2018 Financial Results
- Avapritinib receives Breakthrough Therapy Designation for treatment of advanced SM - - First patient screened in registration-enabling PATHFINDER trial in advanced SM - - Received FDA feedback supporting ...
- PR Newswire•17 days ago
Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International
CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the appointment of Christina Rossi as Chief Commercial Officer, effective October 29, 2018. Blueprint Medicines also announced the appointment of Paul Beresford as General Manager, International. In her new role, Ms. Rossi will join the executive management team and have overall responsibility for commercial strategy and operations, including sales and marketing, for a potential commercial launch of avapritinib in the United States in 2019 and pre-commercial planning across Blueprint Medicines' pipeline.
Markit•21 days agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- PR Newswire•23 days ago
Blueprint Medicines to Report Third Quarter 2018 Financial Results on Tuesday, October 30, 2018
CAMBRIDGE, Mass., Oct. 23, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, October 30, 2018 to report its third quarter 2018 financial results and provide a corporate update. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call. Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases.
- Zacks•23 days ago
Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Markit•26 days agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The net inflows of $1.69 billion over the last one-month into ETFs that hold BPMC are not among the highest of the last year and have been slowing.
- GlobeNewswire•last month
Report: Exploring Fundamental Drivers Behind Masonite International, Chart Industries, Blueprint Medicines, Cross Country Healthcare, HNI, and Paylocity Holding — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•last month
Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers
90 percent of evaluable MTC and PTC patients had tumor reductions 62 percent response rate in MTC patients treated with 300 to 400 mg once daily for at least 24 weeks Patients with longest treatment durations ...
- PR Newswire•last month
Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva
-- Expect to File an IND Application by end of 2018 -- -- Plan to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2019 -- CAMBRIDGE, Mass. , Oct. 1, 2018 /PRNewswire/ -- Blueprint ...
- PR Newswire•2 months ago
Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion
-- Data presented at Late-Breaking Clinical Session of IASLC World Conference on Lung Cancer, and simultaneously published in Cancer Discovery -- CAMBRIDGE, Mass. , Sept. 26, 2018 /PRNewswire/ -- Blueprint ...
- PR Newswire•2 months ago
Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings
CAMBRIDGE, Mass. , Sept. 24, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Markit•2 months agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Markit•2 months agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- PR Newswire•2 months ago
Blueprint Medicines to Present at 16th Annual Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass. , Sept. 5, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ...
Markit•3 months agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BPMC earnings conference call or presentation 1-Aug-18 12:30pm GMT
Q2 2018 Blueprint Medicines Corp Earnings Call
- Motley Fool•3 months ago
What Blueprint Medicines Just Said About Its Future
Investors flocked to the clinical-stage biotech following an encouraging second-quarter update.
- PR Newswire•3 months ago
Blueprint Medicines to Present at Upcoming Investor Conferences in August
CAMBRIDGE, Mass. , Aug. 1, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ...
